Stratus cs

Three different troponin assay methods were used during the course of the study according to local routines. Troponin I (Stratus CS, Siemens, ULN: 0,07 μg/L), Troponin T (AQT 90, Radiometer, ULN: 0,01 μg/L) and hs-Troponin T (Elecsys/Cobas, Roche Diagnostics, ULN: 15 ng/L).

Plasma samples were analyzed using commercially available kits according to the manufacturer’s instructions. High sensitivity C-reactive protein (hsCRP) was measured on a Siemens STRATUS CS in duplicate with a coefficient of variance (CV) of 8.6%.
Soluble CD163 (sCD163) was measured by an in-house sandwich enzyme-linked immunosorbent assay using a BEP-2000 ELISA-analyser (Dade Behring, Deerfield, IL, USA).16 (link)
Soluble endothelial selectin (sE-selectin), soluble vascular cell adhesion molecule1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1), matrix metalloprotease 9 (MMP-9), and total plasminogen activator inhibitor 1 (PAI-1) were analyzed on a multiplex assay (Milipore Corporation, MA, USA) using Luminex^® technology.
All samples were run in duplicates with CV < 12%. CD4 cell counts and HIV RNA levels were done routinely on blood and plasma when collected. Serum lipids were analyzed on a MODULAR ISE 1800 (Roche, Basel, Switzerland).
Metabolic syndrome was defined as having at least two of the following: fasting blood glucose ≥ 5.6 mmol·L⁻¹ or (systolic blood pressure ≥ 135 mm Hg or diastolic blood pressure ≥ 85 mm Hg) or (triglycerides > 1.7 mmol·L⁻¹ or high density lipoprotein <1.03 mmol·L⁻¹).17 (link)
Framingham risk score (FRS) was calculated as the 10-year risk of coronary heart disease (CHD) according to published definitions.18 (link)